Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang
Cancer Res Treat. 2016;48(3):1110-1119.   Published online 2016 Jan 6     DOI:
Citations to this article as recorded by Crossref logo
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment
Y. Wang, Y. Li, L. Xia, K. Niu, X. Chen, D. Lu, R. Kong, Z. Chen, J. Sun
Clinical and Translational Oncology.2018; 20(3): 366.     CrossRef
Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
Xin Li, Han Qi, Gou Qing, Ze Song, Lin Xie, Fei Cao, Xiaoming Chen, Weijun Fan
Thoracic Cancer.2018; 9(8): 1012.     CrossRef
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
Ming‑Szu Hung, Yu‑Hung Fang, Yu‑Ching Lin, Jr‑Hau Lung, Meng‑Jer Hsieh, Ying‑Huang Tsai
Molecular and Clinical Oncology.2018;[Epub]     CrossRef
Risk factors for bone metastasis in completely resected non-small-cell lung cancer
Hui Wang, Yan Zhang, Hui Zhu, Jinming Yu
Future Oncology.2017; 13(8): 695.     CrossRef
Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer
Gino K. In, Jeremy Mason, Sonia Lin, Paul K Newton, Peter Kuhn, Jorge Nieva
Convergent Science Physical Oncology.2017; 3(3): 035002.     CrossRef